New Data on Four Bristol-Myers Squibb Compounds to be Presented at AASLD 2009

Princeton, New Jersey (ots/PRNewswire) -

New data on four Bristol-Myers Squibb Company (NYSE: BMY)
compounds will be presented at the 60th annual meeting of the
American Association for the Study of Liver Diseases (AASLD) in
Boston from October 30 to November 3.

Data will be presented on BARACLUDE(R) (entecavir) in patients
with chronic hepatitis B, and on two compounds in early clinical
development for the treatment of hepatitis C -- BMS-650032, an NS3
inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The
presentation of data on BMS-650032 will mark the first public
disclosure of information about this investigational compound. Data
will also be presented on the investigational compound brivanib, the
first selective dual inhibitor of fibroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) signaling, which is in
Phase 3 development for the treatment of hepatocellular carcinoma.

"The data on Bristol-Myers Squibb compounds that will be
presented at AASLD demonstrate the breadth of our research and
development portfolio and support the company's goal of developing
innovative medicines for patients with various diseases of the
liver," said Elliott Sigal, M.D., Ph.D., executive vice president,
chief scientific officer and president, Research and Development,
Bristol-Myers Squibb. "Our established expertise in viral hepatitis
and oncology uniquely position Bristol-Myers Squibb to be at the
forefront of delivering innovation in the treatment of multiple types
and stages of liver disease. We are proud to be releasing new data on
our significant portfolio of assets."

BARACLUDE, BMS-650032 and brivanib were discovered by
Bristol-Myers Squibb Research and Development. BMS-650032 is
Bristol-Myers Squibb's second small molecule under development for
the treatment of hepatitis C, joining BMS-790052, a first-in-class
investigational NS5A inhibitor of the hepatitis C virus.

PEG-Interferon lambda was discovered by ZymoGenetics, Inc.
Bristol-Myers Squibb and ZymoGenetics announced a global
collaboration for PEG-Interferon lambda and its related development
program earlier this year.

The times, titles and lead authors of the data presentations are
as follows:

Date/Time Presentation Title Lead Author
--------- ------------------ -----------
Hepatitis B
October 31, Efficacy and Safety of Y. Liaw
2:00 - 8:00 Entecavir versus Chang Gung
p.m. EDT Adefovir in Chronic Memorial Hospital,
Hepatitis B Patients Chang Gung
with Evidence of University
Hepatic College of Medicine
Decompensation Taipei, Taiwan
(Abstract #422)
Hepatitis C
November 3, Safety, Tolerability, C. Pasquinelli
12:00 - 12:15 Pharmacokinetics and Bristol-Myers Squibb
p.m. EST Antiviral Activity
following Single- and
Multiple-Dose
Administration of
BMS-650032, a Novel
HCV NS3 Inhibitor, in
Subjects with Chronic
Genotype 1 HCV
Infection (Abstract
#225)
November 3, Genotypic and F. McPhee
8:00 a.m. - Phenotypic Analysis Bristol-Myers Squibb
1:00 p.m. EST of Samples from
HCV-Infected Subjects
Treated with
BMS-650032 in a
Single Ascending Dose
Study (Abstract #1607)
November 3, A Phase 1b A.J. Muir
8:00 a.m. - Dose-Ranging Study of Duke University
1:00 p.m. EST 4 Weeks of School of Medicine
PEG-Interferon (IFN) Durham, North Carolina
Lambda (PEG-rIL-29)
in Combination with
Ribavirin (RBV) in
Patients with Chronic
Genotype 1 Hepatitis
C Virus (HCV)
Infection (Abstract
#1591)
Hepatocellular Carcinoma
November 3, Time-to-Progression R. Finn
8:00 a.m. - Analysis of UCLA Los Angeles, CA
1:00 p.m. EST Second-line Treatment
with Brivanib in
Patients with
Unresectable, Locally
Advanced, or
Metastatic
Hepatocellular
Carcinoma (Abstract
#1683)
November 3, Cell-dependent J. Park
8:00 a.m. - Response of National Cancer Center
1:00 p.m. EST BMS-582664 (Brivanib) Goyang, South Korea
in Hepatocellular
Carcinoma Cells: Gene
Expression Profiling
Study (Abstract #1668)

About BARACLUDE(R)

Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside
analogue indicated for use in adults with chronic hepatitis B
infection with compensated liver disease, evidence of active viral
replication, and either evidence of persistent elevations of the
blood levels of aminotransferases - a marker for liver disease - or
active liver disease as determined by biopsy. BARACLUDE (entecavir)
has been approved in more than 86 countries and regions around the
world.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company
committed to discovering, developing and delivering innovative
medicines that help patients prevail over serious diseases. For more
information, please visit www.bms.com.

BARACLUDE(R) (entecavir) is a registered trademark of
Bristol-Myers Squibb Company.

ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media, Annie Simond, office: +33-1-58-83-65-66, annie.simond@bms.com,
or Investors, John Elicker, +1-609-252-4611, john.elicker@bms.com